Novo Nordisk Patients Seeking Upgrade# Recommendation : CagriSema Reason : Patients already on semaglutide (Wegovy) who need greater weight loss can potentially upgrade to CagriSema within the Novo Nordisk ecosystem once approved, leveraging the same GLP-1 component plus added amylin agonism
R.PaulinoB
Pairs with semaglutide Studied as CagriSema, combining the amylin and incretin pathways
Doctors found a rare mass in a womans stomach and believed her weight-loss medication was the cause Doctors at Brigham and Womens Hospital carried out several tests, including CT scans and specialised imaging
doi: 10.3389/fonc.2024.1414946 Received 09 April 2024 Accepted 08 July 2024 Published 22 July 2024 Volume 14 - 2024 Edited by Gaetano Gallo, Sapienza University of Rome, Italy Reviewed by Sara Claudia Barone, Sapienza University of Rome, Italy Flaminia Genualdo, Sapienza University of Rome, Italy Updates Copyright 2024 Wei, Wang, Yu, Liu and Zong
Zhu et al., 2020)
